Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future

Clinical Pharmacology and Therapeutics

Volumn 101, Issue 5, 2017, Pages 646-656

  Darwich, A S ^a   Ogungbenro, K ^a   Vinks, A A ^b,c   Powell, J R ^d   Reny, J L ^e,f   Marsousi, N ^f   Daali, Y ^e,f   Fairman, D ^g   Cook, J ^h   Lesko, L J ⁱ   McCune, J S ^j   Knibbe, C A J ^k,l   de Wildt, S N ^m,n   Leeder, J S ^o,p   Neely, M ^q   Zuppa, A F ^r   Vicini, P ^s   Aarons, L ^a   Johnson, T N ^t   Boiani, J ^u   Rostami Hodjegan, A ^a,u   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNC Hamner Institute for Drug Safety Sciences   (United States)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g GLAXOSMITHKLINE   (United Kingdom)

^h PFIZER INC   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j USA   (United States)

^k ST ANTONIUS HOSPITAL   (Netherlands)

^l LEIDEN UNIVERSITY   (Netherlands)

^m RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

ⁿ SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^o CHILDREN S MERCY HOSPITAL   (United States)

^p UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^q CHILDREN S HOSPITAL LOS ANGELES   (United States)

^r CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^s MEDIMMUNE LTD   (United Kingdom)

^t CERTARA UK LIMITED   (United Kingdom)

^u Epstein Becker and Green's   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DRUG DOSE; HEALTH CARE PLANNING; OPTIMAL DRUG DOSE; PATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; BIOLOGICAL MODEL; FORECASTING; HUMAN; INTEGRATED HEALTH CARE SYSTEM; PERSONALIZED MEDICINE; TRENDS;

DRUG;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE, INTEGRATED; FORECASTING; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PRECISION MEDICINE;

EID: 85017378738     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.659     Document Type: Article

References (75)

1. Hirsh, J. & Raschke, R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 188S–203S (2004).
2. AGenentech. TAMIFLU(R) (Oseltamivir Phosphate) Capsules, for Oral Suspension: Highlights of Prescribing Information (San Francisco, CA, 2010).
3. van der Zanden, T.M., de Wildt, S.N., Liem, Y., Offringa, M., de Hoog, M. & Dutch Paediatric Pharmacotherapy Expertise Network, N. Developing a paediatric drug formulary for the Netherlands. Arch. Dis. Child. (2016); epub ahead of print.
4. NKFK. Kinderformularium – Vancomycine. (2016). Accessed 14 December 2016.
5. ARoche. CYTOVENE(R)-IV (ganciclovir sodium for injection): Prescribing information. (Nutley, NJ, 1999).
6. Kadambari, S., Heath, P.T., Sharland, M., Lewis, S., Nichols, A. & Turner, M.A. Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units. J. Antimicrob. Chemother. 66, 2647–2650 (2011).
7. Leroux, S. et al. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. Arch. Dis. Child. 100, 394–398 (2015).
8. Lazarou, J., Pomeranz, B.H. & Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).
9. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015).
10. Marsousi, N. et al. Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin. Pharmacol. Ther. 100, 295–304 (2016).
11. Walsh, C. et al. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. Br. J. Clin. Pharmacol. 81, 989–998 (2016).
12. Ogungbenro, K., Patel, A., Duncombe, R., Clark, J. & Lorigan, P. A rational approach to dose optimisation of pembrolizumab using cost analysis and pharmacokinetic modeling and simulation. J. Clin. Oncol. 34, abstr 9547 (2016).
13. McCune, J.S. et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin. Pharmacol. Ther. 85, 615–622 (2009).
14. Zhao, W. et al. First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. Clin. Pharmacokinet. 53, 1005–1018 (2014).
15. Zhao, W., Lopez, E., Biran, V., Durrmeyer, X., Fakhoury, M. & Jacqz-Aigrain, E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch. Dis. Child. 98, 449–453 (2013).
16. Leroux, S. et al. Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. Antimicrob. Agents Chemother. 60, 2039–2042 (2016).
17. Batchelor, H., Appleton, R. & Hawcutt, D.B. Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modeling software. Seizure 33, 8–12 (2015).
18. Su, F., Gastonguay, M.R., Nicolson, S.C., DiLiberto, M., Ocampo-Pelland, A. & Zuppa, A.F. Dexmedetomidine pharmacology in neonates and infants after open heart surgery. Anesth. Anal. 122, 1556–1566 (2016).
19. Smits, A., De Cock, R.F., Allegaert, K., Vanhaesebrouck, S., Danhof, M. & Knibbe, C.A. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob. Agents Chemother. 59, 6344–6351 (2015).
20. Janssen, E.J. et al. Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modeling. Antimicrob. Agents Chemother. 60, 1013–1021 (2016).
21. Krekels, E.H. et al. Evidence-based morphine dosing for postoperative neonates and infants. Clin. Pharmacokinet. 53, 553–663 (2014).
22. Brill, M. et al. Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients. CPT Pharmacometrics Syst. Pharmacol. 5, 20–30 (2016).
23. Diepstraten, J. et al. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur. J. Clin. Pharmacol. 71, 25–34 (2015).
24. Brill, M.J. et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J. Antimicrob. Chemother. 69, 715–723 (2014).
25. De Sousa Mendes, M. et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br. J. Clin. Pharmacol. 80, 1031–1041 (2015).
26. Perera, V. et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin. Drug Metab. Toxicol. 9, 1115–1137 (2013).
27. Fukuda, T. et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J. Clin. Pharmacol. 51, 309–320 (2011).
28. Rasool, M.F., Khalil, F. & Laer, S. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin. Pharmacokinet. 54, 943–962 (2015).
29. Jadhav, P.R. et al. A proposal for scientific framework enabling specific population drug dosing recommendations. J. Clin. Pharmacol. 55, 1073–108 (2015).
30. Younis, I.R. et al. Utility of model based approaches for informing dosing recommendations in specific populations: report from the Public AAPS Workshop. J. Clin. Pharmacol. (2016); epub ahead of print.
31. Vicini, P. et al. Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development. Clin. Pharmacol. Ther. 99, 198–207 (2016).
32. Sheiner, L.B. The intellectual health of clinical drug evaluation. Clin. Pharmacol. Ther. 50, 4–9 (1991).
33. AFDA. PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022. (ed. FDA) (Silver Spring, MD, 2016).
34. Jelliffe, R.W. Administration of digoxin. Dis. Chest. 56, 56–60 (1969).
35. Sheiner, L.B. Computer-aided long-term anticoagulation therapy. Comput. Biomed. Res. 2, 507–518 (1969).
36. Mould, D.R., D'Haens, G. & Upton, R.N. Clinical decision support tools: the evolution of a revolution. Clin. Pharmacol. Ther. 99, 405–418 (2016).
37. Barrett, J.S., Mondick, J.T., Narayan, M., Vijayakumar, K. & Vijayakumar, S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med. Inform. Decision Making 8, 6 (2008).
38. Jelliffe, R.W., Buell, J., Kalaba, R., Sridhar, R. & Rockwell, R. A computer program for digitalis dosage regimens. Math. Biosci. 9, 179–193 (1970).
39. Fuchs, A., Csajka, C., Thoma, Y., Buclin, T. & Widmer, N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin. Pharmacokinet. 52, 9–22 (2013).
40. Roberts, J.A. et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect. Dis. 14, 498–509 (2014).
41. Wagner, C. et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA Public Workshop on PBPK. CPT Pharmacometrics Syst. Pharmacol. 4, 226–230 (2015).
42. Jamei, M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr. Pharmacol. Rep. 2, 161–169 (2016).
43. Neely, M. et al. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. Ther. Drug Monit. 38, 332–342 (2016).
44. Evans, W.E., Relling, M.V., Rodman, J.H., Crom, W.R., Boyett, J.M. & Pui, C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338, 499–505 (1998).
45. Kohn, M.S. et al. IBM's Health Analytics and Clinical Decision Support. Yearbk. Med. Inform. 9, 154–162 (2014).
46. Calvier, E.A. et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 Fade? Clin. Pharmacokinet. (2016); epub ahead of print.
47. Steenholdt, C. et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63, 919–927 (2014).
48. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259–267 (2011).
49. Ince, I., de Wildt, S.N., Tibboel, D., Danhof, M. & Knibbe, C.A. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov. Today 14, 316–320 (2009).
50. Vinks, A.A., Derendorf, H. & Mouton, J.W. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (Springer Science+Business Media, New York, NY, 2014).
51. Neely, M. & Jelliffe, R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J. Clin. Pharmacol. 50, 842–847 (2010).
52. van Lent-Evers, N.A., Mathot, R.A., Geus, W.P., van Hout, B.A. & Vinks, A.A. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther. Drug Monit. 21, 63–73 (1999).
53. Neely, M. & Jelliffe, R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J. Clin. Pharmacol. 48, 1081–1091 (2008).
54. Knibbe, C.A. et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin. Pharmacokinet. 48, 371–385 (2009).
55. Krekels, E.H. et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin. Pharmacokinet. 50, 51–63 (2011).
56. Scaglione, F. et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur. Respir. J. 34, 394–400 (2009).
57. Storset, E. et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients—a prospective, randomized study. Transplantation 99, 2158–2166 (2015).
58. Neely, M. et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob. Agents Chemother. 59, 3090–3097 (2015).
59. Diepstraten, J. et al. Anti-Xa levels 4 h after subcutaneous administration of 5,700 IU nadroparin strongly correlate with lean body weight in morbidly obese patients. Obes. Surg. 22, 791–796 (2012).
60. Darwich, A.S. et al. Evaluation of an in silico PBPK post-bariatric surgery model through simulating oral drug bioavailability of atorvastatin and cyclosporine. CPT Pharmacometrics Syst. Pharmacol 2, e47 (2013).
61. Krauss, M., Tappe, K., Schuppert, A., Kuepfer, L. & Goerlitz, L. Bayesian population physiologically-based pharmacokinetic (PBPK) approach for a physiologically realistic characterization of interindividual variability in clinically relevant populations. PLoS One 10, e0139423 (2015).
62. Tsamandouras, N., Rostami-Hodjegan, A. & Aarons, L. Combining the “bottom-up” and “top-down” approaches in pharmacokinetic modeling: Fitting PBPK models to observed clinical data. Br. J. Clin. Pharmacol. 79, 48–55 (2015).
63. Meesters, N.J., van Dijk, M., Knibbe, C.A., Keyzer-Dekker, C.M., Tibboel, D. & Simons, S.H. Infants operated on for necrotizing enterocolitis: towards evidence-based pain guidelines. Neonatology 110, 190–197 (2016).
64. PhRMA, E.a. Principles for responsible clinical trial data sharing: our commitment to patients and researchers. (2013). Accessed 15 December 2016.
65. Doshi, P. EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. BMJ 347, f5164 (2013).
66. Dollery, C.T. Clinical pharmacology—the first 75 years and a view of the future. Br. J. Clin. Pharmacol. 61, 650–665 (2006).
67. Keely, J.L. & American College of Physicians-American Society of Internal, M. Pharmacist scope of practice. Ann. Intern. Med. 136, 79–85 (2002).
68. Kaboli, P.J., Hoth, A.B., McClimon, B.J. & Schnipper, J.L. Clinical pharmacists and inpatient medical care: a systematic review. Arch. Intern. Med. 166, 955–864 (2006).
69. AStatistics, N.C.f.H. Health, United States, 2010: In Brief (Hyattsville, MD, USA., 2011).
70. Calvert, A.H. et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7, 1748–1756 (1989).
71. Phillips, E. & Mallal, S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol. Diagn. Ther. 13, 1–9 (2009).
72. Yeager, A.M., Wagner, J.E., Jr., Graham, M.L., Jones, R.J., Santos, G.W. & Grochow, L.B. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80, 2425–2458 (1992).
73. Sanathanan, L.P. & Peck, C.C. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control. Clin. Trials 12, 780–794 (1991).
74. AMHRA. Medicines, medical devices and blood regulation and safety—guidance: Medical devices: software applications (apps). (ed. MHRA) (2016).
75. AFDA. Mobile Medical Applications: Guidance for Industry and Food and Drug Administration Staff. (ed. Administration, U.S.D.o.H.a.H.S.F.a.D.) (2015).